Literature DB >> 23903416

Acute myocardial infarction in patients with chronic kidney disease: how are the most vulnerable patients doing?

Gautam R Shroff1, Charles A Herzog.   

Abstract

Patients with advanced chronic kidney disease sustain extremely high mortality rates following acute myocardial infarction. Nauta et al. evaluated temporal trends in 12,087 patients with acute myocardial infarction from a single institution over 24 years and report a reduction in 30-day mortality in the most recent decade for all patients, including patients with chronic kidney disease. This trend is optimistic, but understanding contributory factors would be critical in future studies to further improve survival.

Entities:  

Mesh：

Year:  2013        PMID： 23903416     DOI： 10.1038/ki.2013.151

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  3 in total

Review 1.  Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies.

Authors:  Alexandru Burlacu; Simonetta Genovesi; Carlo Basile; Alberto Ortiz; Sandip Mitra; Dimitrios Kirmizis; Mehmet Kanbay; Andrew Davenport; Frank van der Sande; Adrian Covic
Journal:  J Nephrol       Date:  2020-05-29       Impact factor: 3.902

2.  Aspirin for primary prevention of CVD in CKD: where do we stand?

Authors:  Hugh Gallagher; Mark Lown; Ahmet Fuat; Paul Roderick
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

3.  Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.

Authors:  Hugh Gallagher; Jennifer Dumbleton; Tom Maishman; Amy Whitehead; Michael V Moore; Ahmet Fuat; David Fitzmaurice; Robert A Henderson; Joanne Lord; Kathryn E Griffith; Paul Stevens; Maarten W Taal; Diane Stevenson; Simon D Fraser; Mark Lown; Christopher J Hawkey; Paul J Roderick
Journal:  Trials       Date:  2022-04-21       Impact factor: 2.728
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.